Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29500354 | 0.92 | ACACB (0.47) | ACACBTNFNOD2NOD1OPRM1 | |
| SCHEMBL29500350 | 0.91 | ACACB (0.44) | ACACBTNFNOD2NOD1OPRM1 | |
| SCHEMBL29438615 | 0.89 | DRD2 (0.45) | ACACBTNFNOD2NOD1ALDH1A1 | |
| SCHEMBL30845476 | 0.88 | ACACB (0.43) | ACACBOPRM1OPRD1OPRK1CA2 | |
| SCHEMBL30845462 | 0.88 | OPRM1 (0.51) | OPRM1OPRD1OPRK1CA2CA9 | |
| SCHEMBL29438618 | 0.87 | OPRM1 (0.40) | ACACBOPRM1OPRD1OPRK1MOGAT2 | |
| SCHEMBL29438670 | 0.87 | OPRM1 (0.40) | ACACBOPRM1OPRD1OPRK1MOGAT2 | |
| SCHEMBL29438658 | 0.87 | CA9 (0.42) | ACACBOPRM1OPRD1OPRK1CA2 | |
| SCHEMBL29438663 | 0.86 | OPRM1 (0.43) | ACACBOPRM1OPRD1OPRK1CA2 | |
| SCHEMBL29500296 | 0.85 | ACACB (0.52) | ACACBTNFNOD2NOD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2022057845-A1 | COMPOUND SERVING AS THYROID HORMONE β RECEPTOR AGONIST AND USES OF COMPOUND | 广东东阳光药业有限公司 | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | ACACB 1084/4885TNF 1623/4885NOD2 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.